Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
Abstract The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development. However, important questions regarding SARS-CoV-2 vaccines remain. A case of complete Vogt-Koyana...
Main Authors: | Janaína Jamile Ferreira Saraceno, Guilherme Macedo Souza, Luciana Peixoto dos Santos Finamor, Heloisa Moraes Nascimento, Rubens Belfort |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | International Journal of Retina and Vitreous |
Online Access: | https://doi.org/10.1186/s40942-021-00319-3 |
Similar Items
-
Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
by: Salma Al Bahrani, et al.
Published: (2021-09-01) -
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
by: Glenn A. Marsh, et al.
Published: (2021-05-01) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Sue Ann Costa Clemens, et al.
Published: (2021-10-01) -
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01) -
Is it Vogt-Koyanagi-Harada syndrome?
by: Digambar Dashatwar, et al.
Published: (2015-01-01)